| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 99.3 | 71.6 |
| Gross profit | 74.9 | 53.9 |
| Profit before tax | 10.3 | 1.0 |
| Net income | 9.8 | 1.0 |
| EPS (diluted, $ a share) | $0.25 | $0.03 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +856.6% |
|---|---|
| Revenue, year on year | +38.6% |
| Gross margin | 75.4% |
| Operating margin | 11.6% |
10-Q filed with the SEC, NASDAQ: HROW. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Harrow, Inc.: key numbers
- Share price
- $29.09Close, Nov 16
- Market cap
- $1.09B
- Shares outstanding
- 37.53MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Harrow, Inc.
All →Harrow Investor Presentation
Harrow, Inc. filed a formal corporate presentation to be used by management at the Jefferies Global Healthcare Conference in London. The presentation highlights the company's ophthalmic pharmaceutical portfolio, including core growth brands VEVYE, IHEEZO, and TRIESENCE. The filing is a standard Regulation FD disclosure to provide the investment community with updated strategic and commercial information.
Harrow Financial Results
Harrow reported record third-quarter 2026 revenue of $99.3 million, a 39% increase year-over-year, driven by strong performance in branded products like VEVYE and TRIESENCE. The company reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million but lowered its Adjusted EBITDA outlook to more than $40 million to account for first-half shortfalls and increased R&D spending.
- Term
- Q3 2026
“The third quarter delivered the second-half acceleration we anticipated. Branded products drove record revenue, growing 62% year over year. VEVYE delivered record quarterly revenue, supported by continued prescription growth, improving economics, and increasing productivity from our expanded sales force.”
Mark L. Baum, Chairman and Chief Executive Officer of Harrow
“We expect the fourth quarter to be Harrow’s strongest on record and that second-half revenue will exceed the high end of what we contemplated in March. That said, our updated Adjusted EBITDA outlook reflects both the first half operating shortfall against our original plan and additional spending to accelerate our G-MELT NDA submission, advance important development programs, and integrate TYRVAYA.”
Mark L. Baum, Chairman and Chief Executive Officer of Harrow
Harrow Signs $30M M&A Deal with Viatris Inc.
Harrow, Inc. completed the acquisition of the dry eye disease treatment TYRVAYA from Viatris for $30 million in cash at closing. The deal includes worldwide rights except for Japan, where Viatris will pay Harrow royalties on future sales. Harrow may also pay up to $70 million in contingent milestone payments based on net sales thresholds through 2029.
- Value
- $30M
- Counterparty
- Viatris Inc.